4.5 Article

Amantadine in Parkinson's disease:: lymphocyte subsets and IL-2 secreting T cell precursor frequencies

Journal

EXPERIMENTAL GERONTOLOGY
Volume 36, Issue 10, Pages 1761-1771

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0531-5565(01)00128-0

Keywords

Parkinson's disease; amantadine treatment; B cells; T cells; alloimmune response; interleukin-2

Ask authors/readers for more resources

The antiviral drug amantadine, that is effective in idiopathic Parkinson's disease (PD), may affect the composition and function of peripheral blood lymphocytes. In an explorative study, we therefore compared lymphocyte subpopulations and IL-2 secreting T cell precursors frequencies (HTLp-frequencies) in 15 PD patients without amantadine and six patients on long-term treatment. Five patients were investigated before and three months after the start of treatment. Group comparisons for long-term amantadine treatment showed no differences in subpopulations of B-, T-, and NK cells, and HTLp-frequencies. However, three months after initiation of treatment we noted in all five patients an increase of CD3+CD4+ and decrease of CD3+CD8+ cells, associated with an increase of the CD3+CD4+/CD3+CD8+ ratio. These changes had no effect on the HTLp-frequencies. Thus, at least for a short period of time, amantadine improves the T cell mediated immune system in PD patients. (C) 2001 Elsevier Science Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available